Bristol’s Opdivo Stumbles On Its Way To First-Line Bladder Cancer Indication
The CheckMate-901 trial failed on one of its primary endpoints, but the company will continue the trial to explore additional primary endpoints.
You may also be interested in...
The move marks the second time since last year that Roche has withdrawn a urothelial carcinoma indication after its confirmatory trial failed to show an overall survival benefit.
The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic. The firm stressed growth opportunities ahead for Opdivo, Opdualag and Camzyos.
Even without Lagevrio, Merck's base business grew by double digits; the company raised its revenue guidance for the year.